Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lentigen, a developer of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, have signed a collaborative agreement to co-develop novel cell and protein therapies for hemophilia A.
Subscribe to our email newsletter
Lentigen and Expression Therapeutics will develop two types of treatments for hemophilia: a novel chimeric factor VIII protein for direct injection and a cell therapy that may permanently correct the disorder.
Trent Spencer, president of Expression Therapeutics, said: “The platform technology developed by Expression Therapeutics will be used to advance the treatment of hemophilia A.
“By combining our high expression Factor VIII technology with Lentigen’s protein expression and gene transfer capabilities, we are confident Lentigen is the ideal partner to help bring this technology to the clinic and marketplace.”